Correction to: efficacy and safety of the switch of Triumeq ® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

BMC Pharmacol Toxicol. 2023 Oct 6;24(1):49. doi: 10.1186/s40360-023-00693-8.NO ABSTRACTPMID:37803423 | DOI:10.1186/s40360-023-00693-8

Source: BMC Pharmacology and Toxicology - October 6, 2023 Category: Drugs & Pharmacology Authors: Juli án Olalla Javier P érez-Stachowski Bego ña Tortajada Alfonso Del Arco Efr én Márquez Javier De la Torre Miriam Nieto Jos é María García de Lomas Jos é Luis Prada Javier Garc ía-Alegría Source Type: research